Analysts fell to the sidelines weighing in on Alnylam Pharma (ALNY – Research Report) and Omeros (OMER – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Alnylam Pharma (ALNY)
Oppenheimer analyst Leland Gershell assigned a Hold rating to Alnylam Pharma today and set a price target of $156.00. The company’s shares closed last Thursday at $134.23.
According to TipRanks.com, Gershell is a 1-star analyst with an average return of -1.8% and a 36.7% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alnylam Pharma with a $164.73 average price target.
Needham analyst Serge Belanger maintained a Hold rating on Omeros today. The company’s shares closed last Thursday at $10.96, close to its 52-week low of $8.50.
According to TipRanks.com, Belanger is a 1-star analyst with an average return of -0.5% and a 38.0% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.
Currently, the analyst consensus on Omeros is a Moderate Buy with an average price target of $21.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.